X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Dishman Pharma with Glenmark Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DISHMAN PHARMA vs GLENMARK PHARMA - Comparison Results

DISHMAN PHARMA    Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

GLENMARK PHARMA 
   Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DISHMAN PHARMA GLENMARK PHARMA DISHMAN PHARMA/
GLENMARK PHARMA
 
P/E (TTM) x 25.1 13.6 184.0% View Chart
P/BV x 3.3 3.8 87.6% View Chart
Dividend Yield % 0.7 0.3 199.8%  

Financials

 DISHMAN PHARMA   GLENMARK PHARMA
EQUITY SHARE DATA
    DISHMAN PHARMA
Mar-16
GLENMARK PHARMA
Mar-16
DISHMAN PHARMA/
GLENMARK PHARMA
5-Yr Chart
Click to enlarge
High Rs3741,262 29.7%   
Low Rs129672 19.2%   
Sales per share (Unadj.) Rs197.8270.6 73.1%  
Earnings per share (Unadj.) Rs21.224.9 85.2%  
Cash flow per share (Unadj.) Rs34.734.4 100.9%  
Dividends per share (Unadj.) Rs2.002.00 100.0%  
Dividend yield (eoy) %0.80.2 384.2%  
Book value per share (Unadj.) Rs179.9151.3 118.9%  
Shares outstanding (eoy) m80.69282.16 28.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.33.6 35.6%   
Avg P/E ratio x11.938.9 30.5%  
P/CF ratio (eoy) x7.228.1 25.8%  
Price / Book Value ratio x1.46.4 21.9%  
Dividend payout %9.48.0 117.3%   
Avg Mkt Cap Rs m20,306272,778 7.4%   
No. of employees `0000.810.0 8.3%   
Total wages/salary Rs m5,35513,782 38.9%   
Avg. sales/employee Rs Th19,252.77,614.9 252.8%   
Avg. wages/employee Rs Th6,459.51,374.8 469.9%   
Avg. net profit/employee Rs Th2,064.1700.2 294.8%   
INCOME DATA
Net Sales Rs m15,96176,340 20.9%  
Other income Rs m265356 74.5%   
Total revenues Rs m16,22676,696 21.2%   
Gross profit Rs m4,10314,172 29.0%  
Depreciation Rs m1,0912,691 40.5%   
Interest Rs m9441,789 52.8%   
Profit before tax Rs m2,33410,048 23.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m10-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m6243,028 20.6%   
Profit after tax Rs m1,7117,019 24.4%  
Gross profit margin %25.718.6 138.5%  
Effective tax rate %26.730.1 88.7%   
Net profit margin %10.79.2 116.6%  
BALANCE SHEET DATA
Current assets Rs m11,01859,096 18.6%   
Current liabilities Rs m9,51740,018 23.8%   
Net working cap to sales %9.425.0 37.6%  
Current ratio x1.21.5 78.4%  
Inventory Days Days11075 147.4%  
Debtors Days Days35119 29.2%  
Net fixed assets Rs m16,30439,075 41.7%   
Share capital Rs m161282 57.2%   
"Free" reserves Rs m12,90730,281 42.6%   
Net worth Rs m14,51642,703 34.0%   
Long term debt Rs m4,18924,873 16.8%   
Total assets Rs m29,805111,026 26.8%  
Interest coverage x3.56.6 52.5%   
Debt to equity ratio x0.30.6 49.6%  
Sales to assets ratio x0.50.7 77.9%   
Return on assets %8.97.9 112.3%  
Return on equity %11.816.4 71.7%  
Return on capital %17.517.5 100.1%  
Exports to sales %24.843.3 57.3%   
Imports to sales %3.77.4 50.3%   
Exports (fob) Rs m3,95633,044 12.0%   
Imports (cif) Rs m5965,672 10.5%   
Fx inflow Rs m4,95236,945 13.4%   
Fx outflow Rs m69761,066 1.1%   
Net fx Rs m4,255-24,122 -17.6%   
CASH FLOW
From Operations Rs m2,7863,449 80.8%  
From Investments Rs m-1,529-8,802 17.4%  
From Financial Activity Rs m-9416,986 -13.5%  
Net Cashflow Rs m316934 33.9%  

Share Holding

Indian Promoters % 61.4 48.3 127.1%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 3.7 6.9 53.6%  
FIIs % 12.7 34.4 36.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 22.1 10.5 210.5%  
Shareholders   46,261 56,727 81.6%  
Pledged promoter(s) holding % 35.8 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DISHMAN PHARMA With:   ORCHID PHARMA LTD  CIPLA  TORRENT PHARMA  SUVEN LIFE  WYETH LTD  

Compare DISHMAN PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Finishes on a Flat Note; Dr Reddy's & Lupin Surge over 2%(Closing)

Indian share markets continued to trade just above the dotted line in the afternoon session in a lackluster day of trading. At the closing bell, the BSE Sensex closed higher by 33 points.

Related Views on News

Glenmark Pharma: Lower Zetia Sales leads to Subdued Growth (Quarterly Results Update - Detailed)

May 18, 2017

Base price erosion in the US and lower Zetia sales impacts profits.

Glenmark: Zetia Generics Boost Growth (Quarterly Results Update - Detailed)

Feb 15, 2017

Glenmark has announced its 3QFY16 results. The company has reported 41% YoY growth in net sales and 143.2% YoY increase in net profits. Here is our analysis of the results.

Glenmark: High Costs hit the Bottom line (Quarterly Results Update - Detailed)

Nov 8, 2016

Glenmark has announced its 2QFY16 results. The company has reported 15.7% YoY growth in net sales and 3.5% YoY increase in net profits. Here is our analysis of the results.

Glenmark: Other Income Boosts Profit Growth (Quarterly Results Update - Detailed)

Sep 6, 2016

Glenmark has announced its 1QFY17 results. The company has reported 15.8% YoY growth in net sales and 24% YoY increase in net profits. Here is our analysis of the results.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

More Views on News

Most Popular

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

The Most Important Innovation in Finance Since Gold Coins(Vivek Kaul's Diary)

Aug 10, 2017

Bill connects the dots...between money and growth, real money and real resources, gold and cryptocurrencies...and between gold, cryptocurrencies, and time.

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

Bitcoin Continues Stellar Rise(Chart Of The Day)

Aug 10, 2017

Bitcoin hits an all-time high, is there more upside left?

5 Steps To Become Financially Independent(Outside View)

Aug 16, 2017

Ensure your financial Independence, and pledge to start the journey towards financial freedom today!

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DISHMAN PHARMA SHARE PRICE


May 29, 2017 (Close)

TRACK DISHMAN PHARMA

  • Track your investment in DISHMAN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DISHMAN PHARMA

DISHMAN PHARMA 8-QTR ANALYSIS

COMPARE DISHMAN PHARMA WITH

MARKET STATS